Vigil Neuroscience
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 69
- Market Cap
- $137.1M
- Website
- http://www.vigilneuro.com
- Introduction
Vigil Neuroscience, Inc. engages in the provision of biotechnology research services. Its focus is improving the lives of patients, caregivers, and families affected by neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. The company was founded on June 22, 2020 and is headquartered in Watertown, MA.
Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones
Vigil Neuroscience plans to report Phase 1 data for VG-3927 in Alzheimer’s disease and Phase 2 data for iluzanebart in ALSP in 2025. Achievements include FDA interactions, trial enrollments, and a $40M investment from Sanofi. The company focuses on microglia-targeting therapies for neurodegenerative diseases.
Quanterix Welcomes Ivana Magovčević-Liebisch, Ph.D., J.D. to Board of Directors
Quanterix appoints Ivana Magovčević-Liebisch, Ph.D., J.D. to its Board of Directors, leveraging her 25+ years of biopharmaceutical experience, including founding Vigil Neuroscience and leading key strategic transactions at Ipsen and Teva.
© Copyright 2025. All Rights Reserved by MedPath